Felicitex Therapeutics
Felicitex Therapeutics is an oncology drug development company focused on developing treatments for dormant cancers, which are responsible for resistance, metastasis, and recurrence. They target both dormant and proliferating cancers to improve treatment outcomes for various tumors, including hematopoietic, ovarian, pancreatic, colorectal, osteosarcoma, glioblastoma, and lung cancers. Their approach involves targeting the cancer survival mechanism known as the sleeping niche, aiming to eliminate resistant cancer cells, reduce metastasis, and prevent recurrence.
Industries
Nr. of Employees
small (1-50)
Felicitex Therapeutics
Patents
Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors
US-11202779-B2
View DetailsCombinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors
US-10322128-B2
View DetailsCombinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis
US-10314843-B2
View Details
Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors
US-11202779-B2
View DetailsCombinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors
US-10322128-B2
View DetailsCombinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis
US-10314843-B2
View DetailsProducts
Small-molecule therapeutic candidates targeting tumor cell dormancy (IND-enabling candidates)
A portfolio of small-molecule candidates designed to inhibit mechanisms that maintain cancer cell quiescence, developed to sensitize dormant and proliferating cancer cells to therapy and reduce metastasis and recurrence. Described as three candidates ready for IND-enabling studies.
Small-molecule therapeutic candidates targeting tumor cell dormancy (IND-enabling candidates)
A portfolio of small-molecule candidates designed to inhibit mechanisms that maintain cancer cell quiescence, developed to sensitize dormant and proliferating cancer cells to therapy and reduce metastasis and recurrence. Described as three candidates ready for IND-enabling studies.
Services
Project-based discovery and preclinical development services for oncology small molecules, including target-based inhibitor design, in vitro and in vivo validation, and preparation for IND-enabling studies.
Project-based discovery and preclinical development services for oncology small molecules, including target-based inhibitor design, in vitro and in vivo validation, and preparation for IND-enabling studies.
Expertise Areas
- Cancer dormancy therapeutics
- Small-molecule kinase inhibitor development
- Preclinical validation and animal metastasis models
- Molecular modeling and medicinal chemistry
Key Technologies
- Small-molecule kinase inhibitor chemistry
- Molecular modeling / structure-based design
- Cell-based dormancy/quiescence assays
- Animal metastasis models with clonal barcoding
News & Updates
Combination cancer therapy with DYRK1 inhibitors and inhibitors of the RAS-RAF-MEK-ERK (MAPK) pathway.
Patent granted for treatment of neoplasms using quiescent cell targeting with EGFR inhibitors
Patent granted in March 2022
A Cell Double-Barcoding System for Quantitative Evaluation of Primary Tumors and Metastasis in Animals That Uncovers Clonal-Specific Anti-Cancer Drug Effects.
Combination cancer therapy with DYRK1 inhibitors and inhibitors of the RAS-RAF-MEK-ERK (MAPK) pathway.
Patent granted for treatment of neoplasms using quiescent cell targeting with EGFR inhibitors
Patent granted in March 2022
A Cell Double-Barcoding System for Quantitative Evaluation of Primary Tumors and Metastasis in Animals That Uncovers Clonal-Specific Anti-Cancer Drug Effects.